euglycemic dka glp 1 Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report Beyond Weight Loss: ED Implications

A honlapunk hasznlatval n a tjkoztatsunkat tudomsul veszi

Retatrutide (LY3437943) simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved dual or single agonists such as tirzepatide and semaglutide

Both tirzepatide and liraglutide are Category X, meaning animal studies have shown fetal harm and the risk clearly outweighs any potential benefit during pregnancy

studies provide compelling evidence that semaglutide use in orthopedic surgery is associated with lower rates of infection, readmission, and revision surgery, likely due to improved metabolic control, reductions in systemic inflammation, and weight loss-driven perioperative risk reduction